Citations 2
Reference values for jitter recorded by concentric needle electrodes in healthy controls: A multicenter study
Stålberg, Erik , Sanders, Donald B. , Cooray, Gerald , Leonardis, Lea , Løseth, Sissel , Machado, Flávia Costa Nunes , Martinez‐Aparicio, Carmen , Sandberg, Arne, Smith, Benn, Widenfalk, Johan, Kouyoumdjian, João Aris , Ali, Sajjad , Maldonado, Antonio , Smith, Benn E.
Muscle & Nerve | June 25, 2015 | Volume: 53 | Issue: 3 | Pages: 351-362
ABSTRACT Introduction: The aim of this study was to create reference values for jitter measured with concentric needle electrodes. Methods: Operators worldwide contributed recordings from orbicularis oculi (OO), frontalis (FR), and extensor digitorum (ED) muscles in healthy controls. Criteria for acceptable signal quality were agreed upon in advance. Fifteen or 20 recordings of acceptable quality from each muscle were required for voluntary and electrical stimulation recordings, respectively. Results: Recordings from 59 to 92 subjects were obtained for each muscle and activation type. Outlier limits for mean consecutive difference and individual jitter data for voluntary activation were: OO, 31 and 45 µs; FR, 28 and 38 µs; ED, 30 and 43 µs; and for electrical stimulation they were: OO, 27 and 36 µs; FR, 21 and 28 µs; ED, 24 and 35 µs. Conclusion: Reference jitter values from concentric needle electrode recordings were developed from signals of defined quality while seeking to avoid creating supernormal values. Muscle Nerve 53: 351–362, 2016
Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis
Hobson‐Webb, Lisa D., Hehir, Michael K. , Visser, Amy , Sanders, Donald B. , Burns, Ted M., Crum, Brian, Crum, Brian A.
Muscle & Nerve | April 23, 2015 | Volume: 52 | Issue: 2 | Pages: 211-215
ABSTRACTIntroduction: Mycophenolate mofetil (MMF) is frequently used to treat myasthenia gravis, but there is little information to guide clinicians on the safety of reducing the dose in well‐controlled patients. Methods: This retrospective chart review at 3 institutions identified 92 patients who had undergone MMF taper after achieving either pharmacologic remission or minimal manifestations status. Statistical analysis was performed to assess differences in patient characteristics between patients who had successfully tapered MMF and those who relapsed. Results: Of 92 patients undergoing a taper, 30 relapsed. The relapses were mild, transient, and usually responded to increased MMF dose. MG crisis did not occur. The mean dose at time of relapse was 888 mg/day. Patients with relapses were tapered more quickly (8.4 vs. 62.4 months). Conclusions: Tapering MMF appears safe after years of disease stability. Reducing the dose at a dose of only 500 mg/day every 12 months is recommended. Muscle Nerve 52: 211–215, 2015